首页> 外文OA文献 >Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

【2h】

Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

机译：评价DeVIC±R治疗（地塞米松，依托泊苷，异环磷酰胺和卡铂联合或不联合利妥昔单抗的联合治疗）中计算卡铂剂量作为挽救治疗的复发或难治性非霍奇金淋巴瘤患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Evaluation of a method for calculating carboplatin dosage in DeVIC +/- R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma [J] . Tomono Ayana, Ito Kaori, Hayashi Takahiro, Cancer chemotherapy and pharmacology. . 2016,第2期

机译：评价复发性或难治性非霍奇金淋巴瘤患者用DeVIC +/- R治疗（地塞米松，依托泊苷，异环磷酰胺和卡铂联合或不联合利妥昔单抗）作为挽救治疗的计算卡铂剂量的方法
2. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. [J] . Abali H, Urun Y, Oksuzoglu B, Cancer investigation . 2008,第4期

机译：ICE（异环磷酰胺-卡铂-依托泊苷）与DHAP（胞嘧啶阿拉伯糖苷-顺铂-地塞米松）作为挽救性化疗在复发或难治性淋巴瘤患者中的比较。
3. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. [J] . Abali H, Urun Y, Oksuzoglu B, Cancer investigation . 2008,第4期

机译：ICE（异环磷酰胺-卡铂-依托泊苷）与DHAP（胞嘧啶阿拉伯糖苷-顺铂-地塞米松）作为挽救性化疗用于复发或难治性淋巴瘤患者的比较。
4. PHASE I EVALUATION OF A CARBOPLATIN AND DOXORUBICIN COMBINATION CHEMOTHERAPY PROTOCOL FOR DOGS WITH OSTEOSARCOMA [C] . Jeffrey N Bryan, Kerry C Rissetto, Carolyn J Henry, Annual conference of the Veterinary Cancer Society . 2008

机译：患有骨肉瘤的犬犬的Carboplatin和多柔比星组合化疗方案的I级评估
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone etoposide ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma [O] . Ayana Tomono, Kaori Ito, Takahiro Hayashi, -1

机译：评价DeVIC±R治疗（地塞米松依托泊苷异环磷酰胺和卡铂联合或不联合利妥昔单抗的联合治疗）中计算卡铂剂量作为挽救治疗的复发或难治性非霍奇金淋巴瘤患者
7. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma. [O] . Tiffany Tang, Peter Martin, Nagavalli Somasundaram, 2020

机译：I阶段研究Selinexor与地塞米松，Ifosfamide，Carboplatin，复发或难治性外周T细胞或Naturalkiller / T细胞淋巴瘤患者的依托普齐德化疗。

Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅